Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Akebia Therapeutics

OPKO Health

Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Biotech Penny Stocks to Watch With High Volume in 2021

Datasea Inc

Hut 8 Mining Corp

A new week means a new opportunity to trade penny stocks; here's 3 to watch The post Top Penny Stocks to Invest In 2021? 3 For Your List Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Invest In 2021? 3 For Your List Next Month

Kadmon Hlds

9 Meters Biopharma

Performant Financial

Analysts say these are penny stocks to buy. Do you agree?

7 Penny Stocks To Buy According To Analysts With Targets Up To 316%

NEW YORK, July 14, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will participate in two investor conferences: the BTIG Virtual Biotechnology Conference on August 9 th and 10th and the Canaccord Growth Conference on August 11 th and 12th. Raj Mehra, Ph.D.

Seelos Therapeutics to Participate in Two Investor Conferences in August

Acasti Pharma

Cellect Biotechnology Ltd

Aerpio Pharmaceuticals Inc

Check-Cap

SCWorx Corp

Biotech penny stocks are in focus; here's 4 to watch right now The post Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist

NEW YORK, July 7, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein-expression from a study of SLS-004 in an in-vivo rodent model utilizing CRISPR-dCas9 gene therapy technology. A single dose of SLS-004 produced a therapeutically desirable 27% reduction on SNCA mRNA and a 40% reduction in SNCA protein expression.

Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Disease Pathology

NEW YORK, July 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in Part 2, the double-blind, placebo-controlled cohort, of its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). "The goal of the development of SLS-002 in treating suicidal patients is to radically change the current standard of care.

Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Antares Pharma

GT Biopharma Inc

ObsEva

Ocugen, Inc.

Odonate Therapeutics

Palatin Technologies

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

Seelos Therapeutics, Inc. (NASDAQ: SEEL) shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an $8 price target. Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders.

Why Seelos Therapeutics Is Moving Today

Senmiao Technology

Camber Energy

Color Star Technology

Castor Maritime Inc

GTT Communications

Marin Software

Staffing 360 Solutions

With July in full swing, which penny stocks are you watching this month? The post Hot Penny Stocks to Buy For the Rest of 2021?

Hot Penny Stocks to Buy For the Rest of 2021? Check These 8 Out

The stock price of Seelos Therapeutics Inc (NASDAQ: SEEL) increased by over 10% pre-market. This is why it happened.

SEEL Stock Price Increases Over 10% Pre-Market: Why It Happened

NEW YORK, June 28, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has been added to the Russell 2000®, Russell 3000® and Russell Microcap ® Indexes effective after the U.S. markets open today, June 28, 2021, as part of the 2021 Russell US Indexes Reconstitution. "The inclusion of Seelos into the Russell 2000, 3000 and microcap indexes should help increase our exposure in the investment community and is a tribute to the progress we have made building the company over the past year," said Raj Mehra, PhD, Chairman and CEO of Seelos.

Seelos Therapeutics Added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes

Seelos is developing a ketamine drug for suicidal ideation.

Seelos: Superior Data, But Early Stage

Jaguar Health

Teligent

Biotech penny stocks are heating up as Covid cases decline; which small-caps are on your watchlist? The post Trading Biotech Penny Stocks?

Trading Biotech Penny Stocks? Check These 3 Out

The company has been included in the first U.S. psychedelics-focused ETF.

Why Seelos Therapeutics Stock Is Jumping Today

NEW YORK, June 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been included in the Defiance Next Gen Altered Experience ETF, the first U.S. listed Exchange Traded Fund (ETF) focused on psychedelics which began trading on Friday, May 28 th on the New York Stock Exchange under the symbol PSY. Seelos' inclusion is based on its lead program SLS-002 (intranasal racemic ketamine), which recently released positive top-line data from Part 1, the open-label cohort, of its potentially registrational Proof-of-Concept study for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics

Seelos Therapeutics Inc's (NASDAQ: SEEL) Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Under the orphan designation, Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees, and market exclusivity.

Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe

NEW YORK, May 27, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Under orphan designation in the European Union (EU), Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity.

Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)

NEW YORK, May 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to Seelos from this offering are expected to be approximately $64.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos.

Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Vinco Ventures

Cinedigm

Toughbuilt Industries Inc

Looking for penny stocks to buy at a steal? Check these 3 out for some watchlist inspiration The post These 4 Penny Stocks Are Down Today, Time to Buy the Dip?

These 4 Penny Stocks Are Down Today, Time to Buy the Dip?

NEW YORK, May 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on Wednesday, May 26, 2021. Raj Mehra, Ph.D.

Seelos Therapeutics to Participate in The Benchmark Company Healthcare Conference

NEW YORK, May 20, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 shares of its common stock, at a price to the public of $3.10 per share. In addition, the Company granted the underwriters a 30-day option to purchase up to 2,903,226 additional shares of its common stock.

Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

US Well Services

22nd Century Group

Top penny stocks in 2021? Check these 3 out for some watchlist inspiration The post Best Penny Stocks to Invest in 2021?

Best Penny Stocks to Invest in 2021? Here's 3 To Check Out

NEW YORK, May 19, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Seelos Therapeutics Announces Proposed Public Offering of Common Stock

Investors need to pay close attention to Seelos (SEEL) stock based on the movements in the options market lately.

Do Options Traders Know Something About Seelos (SEEL) Stock We Don't?

News for Seelos Therapeutics Stock (SEEL)